Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparison of the efficacy of varespladib and coral snake antivenom against the activities of the Amazon coral snake (Micrurus spixii) venom.

Toxicon : official journal of the International Society on Toxinology·2026

Same author

Predicting cross reactivity between the fire ant venom allergen Sol i 3 and the antigen 5 from vespid venoms based on molecular modeling computing.

Journal of immunotoxicology·2026

Same author

The action of marimastat, a metalloprotease inhibitor, on the coagulant, hemorrhagic, and neuromuscular activities of Lachesis muta (South American bushmaster) venom.

Toxicon : official journal of the International Society on Toxinology·2026

Same author

Properties and Pharmacology of Scorpion Toxins and Their Biotechnological Potential in Agriculture and Medicine.

Toxins·2025

Same author

Electrophysiological modulation of cholinergic neurotransmission by biologically active peptides from Bothrops bilineatus (Viperidae: Crotalinae) venom.

Archives of toxicology·2025

Same author

An Experimental Model of Acute Pulmonary Damage Induced by the Phospholipase A<sub>2</sub>-Rich Venom of the Snake <i>Pseudechis papuanus</i>.

Toxins·2025

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in

Carina Malaguti¹, Conceição Aparecida Vilella, Karla Priscila Vieira

¹Laboratory of Immunology & Experimental Allergy - Department of Internal Medicine, School of Medical Sciences, State University of Campinas, Campinas, SP, Brazil.

International Immunopharmacology

|April 30, 2008

Summary

Diacerein, an anti-inflammatory drug, was studied in non-obese diabetic (NOD) mice, a model for type 1 diabetes mellitus. Diacerein reduced diabetes onset by downregulating pro-inflammatory cytokines, suggesting a therapeutic potential for type 1 diabetes.

More Related Videos

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Related Experiment Videos

Last Updated: Jul 5, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Area of Science:

Immunology
Endocrinology
Pharmacology

Background:

Type 1 diabetes mellitus (DM-1) in non-obse diabetic (NOD) mice closely mimics human disease, involving islet destruction driven by T lymphocytes and pro-inflammatory cytokines like IL-1beta.
Diacerein exhibits anti-inflammatory properties by inhibiting IL-1, but its precise immune-modulating mechanisms in DM-1 are not fully understood.

Purpose of the Study:

To investigate the relationship between IL-1beta, IFN-gamma, IL-12, and TNF-alpha expression, diabetes onset, and morphological changes in NOD mice treated with diacerein.
To evaluate the dose-dependent effects of diacerein (5, 10, and 50 mg/kg/day) on immune markers and diabetes progression.

Main Methods:

NOD mice were treated with varying doses of diacerein or saline (control).
Serum and pancreatic islets were analyzed for cytokine expression (IL-1beta, IFN-gamma, IL-12, TNF-alpha) using mRNA and protein assays.
High-performance liquid chromatography (HPLC) was used to detect diacerein and its metabolite, rhein, in serum and pancreatic tissues.

Main Results:

Diacerein treatment (5 and 10 mg/kg/day) led to upregulation of islet mRNA and downregulation of serum IL-1beta, IL-12, and TNF-alpha compared to controls.
A higher dose (50 mg/kg/day) of diacerein increased serum IFN-gamma concentration.
Diacerein and rhein were detected in the serum and pancreas of treated mice, confirming drug presence and bioavailability.

Conclusions:

Diacerein demonstrates a dose-dependent reduction in diabetes frequency in NOD mice.
The drug effectively downregulates pro-inflammatory cytokines (IL-1beta, TNF-alpha, IFN-gamma, IL-12) at post-transcriptional or post-translational levels, suggesting a therapeutic mechanism for type 1 diabetes.
Diacerein's presence in serum and pancreas supports its potential as a treatment for autoimmune diabetes.